Takeda To Hunt For New CNS Therapeutics With Heptares' Technology
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical Company, which has targeted new central nervous system drugs as a core therapeutic research area, entered into a $100 million research collaboration April 11 with the U.K. biotech, Heptares Therapeutics Ltd., to characterize a G-protein coupled receptor (GPCR) believed to play a role in CNS disorders
You may also be interested in...
$400m Heptares Acquisition To Drive Sosei’s R&D
Sosei is to pay up to $400 million to acquire the UK structure-based drug design specialist Heptares Therapeutics in a move that the Japanese firm hopes will bring fresh fuel to its R&D engine, complementing its existing nanotech and peptide technologies.
Deals Of The Week: Shire/Heptares, NicOx/Altacor, UCB/Oxford University
This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.
Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains
TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success